Tetz, G.; Kardava, K.; Vecherkovskaya, M.; Hahn, A.; Tsifansky, M.; Koumbourlis, A.; Tetz, V. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. Journal of Clinical Microbiology 2023, 61, doi:10.1128/jcm.01558-22.
Tetz, G.; Kardava, K.; Vecherkovskaya, M.; Hahn, A.; Tsifansky, M.; Koumbourlis, A.; Tetz, V. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. Journal of Clinical Microbiology 2023, 61, doi:10.1128/jcm.01558-22.
Tetz, G.; Kardava, K.; Vecherkovskaya, M.; Hahn, A.; Tsifansky, M.; Koumbourlis, A.; Tetz, V. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. Journal of Clinical Microbiology 2023, 61, doi:10.1128/jcm.01558-22.
Tetz, G.; Kardava, K.; Vecherkovskaya, M.; Hahn, A.; Tsifansky, M.; Koumbourlis, A.; Tetz, V. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. Journal of Clinical Microbiology 2023, 61, doi:10.1128/jcm.01558-22.
Abstract
Cystic fibrosis (CF) is characterized by mutations of CFTR that lead to increased viscous secretions, bacterial colonization and recurrent infections. Chronic P. aeruginosa infection in persons with CF is associated with progressive and accelerated lung function decline despite aggressive antibiotic treatment. We report the management of respiratory infections in persons with CF with antibiotic therapy that was based on the recommendations of AtbFinder, a novel, rapid, culture-based diagnostic test system that employs a novel paradigm of antibiotic selection. AtbFinder mimics bacterial interactions with antibiotics at concentrations that can be achieved in affected tissues or organs, and models conditions of interbacterial interactions within polymicrobial biofilms. This open-label, single-arm, investigator‐initiated clinical study was designed to identify the efficacy of antibiotics selected using AtbFinder in persons with CF. Microbiological and clinical parameters were assessed following the change of antibiotic therapy to antibiotics selected with AtbFinder between January 2016 and December 2018 and retrospectively compared with clinical data collected between January 2013 and December 2015.We enrolled 35 persons with CF (33 with chronic P. aeruginosa colonization). Antibiotics selected using AtbFinder resulted in clearance of P. aeruginosa in 81.8% of subsequent cultures, decreased pulmonary exacerbations from 1.21 per patient per annum to 0, and an increase in predicted FEV1% up to 28.4% from baseline. The number of systemic antibiotic courses used in patients after switching to the AtbFinder selected therapy was reduced from 355 to 178. These findings describe the superiority of antibiotic regimens selected with AtbFinder compared with routine antimicrobial susceptibility testing.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
